We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+24.92%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$121M
AUM Growth
+$12.8M
Cap. Flow
-$3.03M
Cap. Flow %
-2.51%
Top 10 Hldgs %
72.03%
Holding
125
New
60
Increased
12
Reduced
11
Closed
25

Top Buys

Rank Stock Value
1
WTW icon
Willis Towers Watson
WTW
+$3.94M
2
TECD
Tech Data Corp
TECD
+$3.53M
3
CZR
Caesars Entertainment Corporation
CZR
+$3.46M
4
TIF
Tiffany & Co.
TIF
+$3.28M
5
LOGM
LogMein, Inc.
LOGM
+$2.89M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$19.3M
2
CY
Cypress Semiconductor
CY
+$6.27M
3
S
Sprint Corporation
S
+$5.7M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$3.04M
5
MLNX
Mellanox Technologies, Ltd.
MLNX
+$2.79M

Sector Composition

Rank Sector Weight
1 Technology 43.2%
2 Healthcare 20.87%
3 Financials 13.46%
4 Consumer Discretionary 9.87%
5 Communication Services 0.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KURA icon
26
Kura Oncology
KURA
$874M
$485K 0.4%
+29,741
New +$429K
NVO
27
Novo Nordisk
NVO
$211B
$485K 0.4%
14,800
-3,800
-20% -$121K
KOD icon
28
Kodiak Sciences
KOD
$2.72B
$479K 0.4%
+8,839
New +$498K
NGNE icon
29
Neurogene
NGNE
$729M
$474K 0.39%
+1,428
New +$372K
DCPH
30
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$461K 0.38%
+7,717
New +$413K
CRNX icon
31
Crinetics Pharmaceuticals
CRNX
$8.93B
$450K 0.37%
+25,701
New +$438K
IGMS
32
DELISTED
IGM Biosciences
IGMS
$449K 0.37%
+6,146
New +$373K
TRIL
33
DELISTED
Trillium Therapeutics Inc.
TRIL
$449K 0.37%
+55,556
New +$344K
SWTX
34
DELISTED
SpringWorks Therapeutics
SWTX
$447K 0.37%
+10,649
New +$379K
CNST
35
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$447K 0.37%
+14,888
New +$536K
TCDA
36
DELISTED
Tricida, Inc. Common Stock
TCDA
$446K 0.37%
+16,235
New +$442K
INSM icon
37
Insmed
INSM
$29.4B
$438K 0.36%
+15,906
New +$377K
RLMD icon
38
Relmada Therapeutics
RLMD
$484M
$434K 0.36%
+9,693
New +$410K
CDXS icon
39
Codexis
CDXS
$161M
$433K 0.36%
+38,009
New +$429K
SGEN
40
DELISTED
Seagen Inc. Common Stock
SGEN
$433K 0.36%
+2,549
New +$380K
KDMN
41
DELISTED
Kadmon Holdings, Inc.
KDMN
$433K 0.36%
+84,612
New +$379K
ASND icon
42
Ascendis Pharma A/S
ASND
$16.8B
$428K 0.35%
+2,893
New +$397K
FATE icon
43
Fate Therapeutics
FATE
$322M
$428K 0.35%
+12,463
New +$371K
ACAD icon
44
Acadia Pharmaceuticals
ACAD
$5.06B
$426K 0.35%
+8,794
New +$422K
IOVA icon
45
Iovance Biotherapeutics
IOVA
$2.9B
$425K 0.35%
+15,481
New +$509K
VSTM icon
46
Verastem
VSTM
$615M
$425K 0.35%
+20,588
New +$545K
ALEC icon
47
Alector
ALEC
$189M
$424K 0.35%
+17,352
New +$479K
STOK icon
48
Stoke Therapeutics
STOK
$2.08B
$423K 0.35%
+17,734
New +$421K
ARGX icon
49
argenx
ARGX
$54.2B
$422K 0.35%
+1,872
New +$332K
BPMC
50
DELISTED
Blueprint Medicines
BPMC
$421K 0.35%
+5,396
New +$365K
1
2
3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

HighVista Strategies's Q2 2020 Portfolio in Review

As of Q2 2020, HighVista Strategies held 125 positions worth $121M, up 12% from $108M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

HighVista Strategies's Q2 2020 filing shows 60 new, 12 increased, 11 reduced and 25 closed positions. Its largest new stake was Caesars Entertainment Corporation: 342,418 shares worth $4.15M. The largest sale was Allergan plc, an estimated $19.3M.

By sector, the portfolio is most concentrated in Technology at 43% of assets, up from 40% a quarter earlier, followed by Healthcare and Financials.

  • HighVista Strategies's largest Q2 2020 buy was Caesars Entertainment Corporation: 342,418 shares worth $4.15M.
  • HighVista Strategies added most to Willis Towers Watson in Q2 2020, an estimated $3.94M increase.
  • HighVista Strategies's biggest Q2 2020 reduction was Silvergate Capital Corporation, cutting an estimated $2.58M.
  • HighVista Strategies fully exited Allergan plc in Q2 2020, selling an estimated $19.3M.
  • HighVista Strategies's ten largest holdings make up 72% of its $121M portfolio in Q2 2020.
  • HighVista Strategies opened 60 new positions and closed 25 in Q2 2020.
  • HighVista Strategies's portfolio value rose 12% quarter-over-quarter to $121M.

Based on HighVista Strategies's 13F filing for Q2 2020, filed 14 Aug 2020.